| abstract |
The invention concerns phenoxypropanolamines of formula (I) wherein: R1 represents a hydrogen, a -S(O)z-(C1-C4)Alk-R' group, R' being H, phenyl or (C1-C4) alkoxy), -NHSO2-(C1-C4) Alk, NHCO(C1-C4) Alk; m and n are each independently 0, 1 or 2; R2 and R3 represent independently a hydrogen, a (C5-C6) alkyl, (C3-C6) cycloalkyl, (C1-C4) alkoxy, hydroxy(C1-C4)alkyl, (C1-C4) alkoxy-(C1-C4)alkyl, mono-or di-(C1-C4)Alk-amino(C1-C4)alkyl, pyrrolidino-(C1-C4)alkyl, phenylamino, (C2-C4)alkenyl group, or an aromatic or heteroaromatic group substituted or not with a group R4; R2 and R3 can also together constitute a saturated or unsaturated cycle of 3 to 6 atoms capable of bearing a (C1-C4) alkyl, amino(C1-C4)alkyl, carbamoyl or benzyl substituent; R4 represents a hydrogen or a halogen, a -CO(C1-C4)Alk group or a -NHSO2-(C1-C4)Alk group; a (C1-C4)Alk group, a (C1-C4)alkoxy group, a halogen, -COOH, -COO(C1-C4)Alk, -CN, -CONR3R4, -NO2, -SO2NH2, -NHSO2(C1-C4)Alk; z is 1 or 2; and their salts and solvates. Said compounds have an agonist activity with respect to β-3 adrenergic receptors. |